Medigen Biotechnology Corp. (TPEX:3176)

Medigen Biotechnology Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,388	2,223	2,041	2,145	2,207
Short-Term Investments	1,200	2,364	3,040	800	-
Trading Asset Securities	0.59	0.49	54.23	53.6	54.2
Cash & Short-Term Investments	2,588	4,588	5,135	2,998	2,261
Cash Growth	-43.58%	-10.67%	71.28%	32.62%	146.78%
Accounts Receivable	286.07	328.89	398.31	800.22	151.21
Other Receivables	87.61	124.72	66.37	35.46	130.51
Receivables	373.67	453.61	464.69	835.68	281.72
Inventory	645.06	546.91	692.62	752.87	323.29
Prepaid Expenses	22.76	33.61	382.35	99.59	-
Other Current Assets	31.36	86.4	57.93	231.96	155.9
Total Current Assets	3,661	5,708	6,733	4,918	3,022
Property, Plant & Equipment	1,981	2,043	2,198	2,189	2,166
Long-Term Investments	640.35	292.87	307.33	363.71	156.49
Goodwill	76.18	76.18	76.18	76.18	76.18
Other Intangible Assets	24.18	30.36	36.9	48.08	79.34
Long-Term Deferred Tax Assets	253.21	327.5	480.94	522.18	555.68
Other Long-Term Assets	74.12	49.1	150.42	81.75	97.02
Total Assets	6,710	8,527	9,982	8,199	6,152
Accounts Payable	125.29	122.57	185.01	163.94	110
Short-Term Debt	229.8	402.6	328	300	475
Current Portion of Long-Term Debt	47.35	1,728	28.86	21.34	21.39
Current Portion of Leases	22	17.32	13.13	3.32	3.02
Current Income Taxes Payable	12.73	24.63	22.99	-	-
Current Unearned Revenue	231.23	135	130.4	244.42	113.92
Other Current Liabilities	256.82	349.37	343.94	331.89	210.47
Total Current Liabilities	925.22	2,780	1,052	1,065	933.8
Long-Term Debt	411.25	449.1	2,129	470.77	486.37
Long-Term Leases	308	267.53	275.32	196.64	195.67
Long-Term Deferred Tax Liabilities	14.08	14.15	14.24	14.35	18.15
Other Long-Term Liabilities	10.28	10.28	29.53	15.89	7.62
Total Liabilities	1,672	3,530	3,511	1,773	1,653
Common Stock	1,393	1,393	1,394	1,394	1,390
Additional Paid-In Capital	536.79	968.14	1,562	1,109	1,101
Retained Earnings	-352.66	-747.51	-727.98	-52.82	-631.38
Comprehensive Income & Other	4.69	-22.45	-34.12	-54.96	-44.37
Total Common Equity	1,582	1,592	2,194	2,394	1,815
Minority Interest	3,456	3,405	4,277	4,032	2,684
Shareholders' Equity	5,038	4,997	6,471	6,426	4,499
Total Liabilities & Equity	6,710	8,527	9,982	8,199	6,152
Total Debt	1,018	2,865	2,774	992.07	1,181
Net Cash (Debt)	1,570	1,723	2,361	2,006	1,079
Net Cash Growth	-8.86%	-27.03%	17.68%	85.87%	-
Net Cash Per Share	11.27	12.36	16.97	14.44	7.77
Filing Date Shares Outstanding	139.31	139.35	139.45	139.36	138.99
Total Common Shares Outstanding	139.31	139.35	139.45	139.36	138.99
Working Capital	2,736	2,928	5,681	3,853	2,088
Book Value Per Share	11.36	11.42	15.73	17.18	13.06
Tangible Book Value	1,482	1,485	2,081	2,270	1,660
Tangible Book Value Per Share	10.64	10.66	14.92	16.29	11.94
Land	330.29	330.29	354.04	354.04	354.04
Buildings	1,468	1,465	1,506	1,500	1,495
Machinery	1,233	1,266	1,240	1,178	1,002
Construction In Progress	2.57	21.37	14.54	4.7	17.9
Leasehold Improvements	9.35	3.34	3.03	2.55	1.89

Source: S&P Global Market Intelligence. Standard template. Financial Sources.